Navigation Links
Vista Partners Updates Coverage; Maintains $3.20 Target Price
Date:10/13/2008

LOS ANGELES, Oct. 13 /PRNewswire/ -- Vista Partners announced today that it has updated its coverage on American Bio Medica Corporation (Nasdaq: ABMC) and maintains its twelve month target price of $3.20. Ross Silver, Director of Research at Vista Partners stated, "Sales internationally continue to increase and sales from the Company's lab alliance, which give ABMC's products exposure in numerous testing centers, continue to increase as well. The Company recently received CLIA approval from the FDA. The CLIA approval will significantly broaden the Company's customer base and we believe ABMC's valuation will increase dramatically in the near future."

About Vista Partners:

Vista Partners provides independent, equity research to institutional and individual investors, with a focus on publicly traded small capitalization companies. With offices in Los Angeles and San Francisco, Vista Partners is one of the fastest growing independently owned equity research firms. Vista Partners professional staff has backgrounds in finance, corporate communications and investment banking. More information is available at http://www.vistap.com.

About American Bio Medica Corporation:

American Bio Medica Corporation is a biotechnology company that develops manufactures and markets accurate, cost-effective immunoassay diagnostic test kits, including some of the world's most effective point of collection tests for drugs of abuse. The Company and its worldwide distribution network target the workplace, government, corrections, clinical and educational markets. ABMC's Rapid Drug Screen(R), Rapid One(R), Rapid TEC(R), RDS(R) InCup(R), Rapid TOX(R) and Rapid TOX Cup(R) products test for the
'/>"/>

SOURCE Vista Partners
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Synvista Therapeutics Posts Letter to Stockholders on Web Site
2. Vista Partners Updates Coverage on Inovio Biomedical Corporation (Amex: INO); $3.57 Price Target
3. Vista Partners Updates Coverage on Raptor Pharmaceuticals Corp. (OTC Bulletin Board: RPTP)
4. Vista Partners Initiates Coverage on MediciNova Inc. (Nasdaq: MNOV)
5. Vista Partners Initiates Coverage on Synvista Therapeutics, Inc. (AMEX: SYI)
6. Synvista Therapeutics Announces Initiation of the BREAK Study of Alagebrium for Diastolic Heart Failure
7. Synvista Therapeutics to Present at Acumen BioFin Rodman & Renshaw 5th Annual Global Healthcare Conference
8. Synvista Therapeutics Increases Commercial Focus by Appointing David C. Tantillo Senior Director of Marketing and Sales
9. Vista Partners Updates Coverage; Maintains $3.20 Target Price
10. Bayer HealthCare Pharmaceuticals Introduces VistaTrak(TM) an Innovative Contrast Media Management System
11. Synvista Therapeutics Highlights Newly Published Data Demonstrating the Value of Haptoglobin Genotype Testing In People with Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... , Alemania, April 27, 2015 ... nuevo receptor utilizando tecnología de descubrimiento de biomarcador computacional  ... el tratamiento de millones de pacientes con cáncer   ... ha recibido una patente en Europa titulada "Tissue Protective ... Molecular Health de que EPHB4 es un nuevo receptor ...
(Date:4/27/2015)... 2015 Deadly viruses such as Ebola ... of the University City Science Center's Port ... , With a $4.5 million Phase 2 SBIR grant ... Phelix Therapeutics is focused on therapies for unmet ... company is developing first-in-class protease inhibitors based on a ...
(Date:4/27/2015)... , April 27, 2015   Aratana ... pet therapeutics company focused on the licensing, development ... animals, today provided commentary on clinical study data ... a poster session at the American Association for ... ADXS31-164 is a novel Lm -LLO immunotherapy ...
(Date:4/27/2015)... HEIDELBERG , Germany , April ... need in treatment of millions of cancer patients   ... a patent in Europe entitled ... Health,s discovery that EPHB4 is a novel receptor for Erythropoietin ... stimulates the production of red blood cells and is ...
Breaking Biology Technology:Molecular Health obtiene la patente para un nuevo receptor 2Molecular Health obtiene la patente para un nuevo receptor 3New Resident of Science Center’s Port Business Incubator Targets SARS and Ebola 2Aratana Therapeutics Comments on ADXS31-164 (AT-014) Study Data Presented During Poster Session at the American Association for Cancer Research (AACR) Annual Meeting 2015 2Molecular Health Gains Patent for Novel Receptor Utilizing Computational Biomarker Discovery Technology 2
... Symbol: MSEDMONTON, April 14 /PRNewswire-FirstCall/ - BioMS Medical Corp. ... multiple sclerosis (MS), today announced that the independent Data ... phase III MAESTRO-03 trial of dirucotide in patients with ... recommended that the trial continue as per the protocol. ...
... Therapeutics, Inc., the leader in fragment-based lead discovery ... successful completion of the first phase of its ... of Biogen Idec (Nasdaq: BIIB ). ... to Zenobia,s technology and expertise in structural biology, ...
... Neptune Technologies & Bioressources Inc. ("Neptune") (NASDAQ.NEPT - TSX.V.NTB) ... fiscal 2009 third quarter and nine-month period ended February ... its fiscal year 2009 now ending on February, 28. ... ended February 28, 2009 in the range of $3,400,000 ...
Cached Biology Technology:BioMS Medical's phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board 2Zenobia Therapeutics Successfully Completes Initial Phase of Its Service Agreement With Syntonix Pharmaceuticals 2Neptune Technologies to expect Record Revenues; Fiscal 2009 Third Quarter and Year-End Results 2Neptune Technologies to expect Record Revenues; Fiscal 2009 Third Quarter and Year-End Results 3Neptune Technologies to expect Record Revenues; Fiscal 2009 Third Quarter and Year-End Results 4Neptune Technologies to expect Record Revenues; Fiscal 2009 Third Quarter and Year-End Results 5
(Date:4/2/2015)... , April 2, 2015 ... DERMALOG by far outperforms the strongest competitors, showing ... high accuracy, the system is capable of a ... speed proves up to be ten times faster ... its runner-up performance.      (Photo: ...
(Date:4/1/2015)... Medisafe ™, the leading global medication management platform with ... Android smartphones and tablets, announces today that ... allow patients to track and correlate their adherence directly ... be able to visualize in real-time how taking medication ... glucose levels and blood pressure. "Patients need ...
(Date:3/24/2015)... DUBLIN , Mar. 24, 2015 Research and ... addition of the "Global Iris Recognition Market 2015-2019" ... forecast the Global Iris Recognition market to grow at ... This report covers the present scenario and ... for the period 2015-2019. To calculate the market size, ...
Breaking Biology News(10 mins):DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2
... from layers 3.46 billion years old suggests that not only ... atmosphere was as oxygen rich as it is today, according ... ways similar to the way this rock forms around hydrothermal ... have assumed that the hematite in ancient rocks formed by ...
... scientists from the National Institute of Oceanography and the ... research vessel Polarstern. The cooperative project Lohafex has yielded ... has dampened hopes on the potential of the Southern ... 2 ) and thus mitigate global warming. On 17 ...
... a common ingredient in over-the-counter skin creams. Recent results ... it is associated with major environmental risks. , "The ... in the ocean that has a direct impact on ... Porsbring. When Euorpean authorities assess environmental risks, they ...
Cached Biology News:Deep-sea rocks point to early oxygen on Earth 2Lohafex provides new insights on plankton ecology 2Lohafex provides new insights on plankton ecology 3Lohafex provides new insights on plankton ecology 4Drug used to treat skin conditions is a marine pollutant 2
... Special optically clear polystyrene formulation , High ... applications , Plates are certified for ... variation , Eight-well strips fit snugly ... while in use even if turned upside ...
12 breakable polypropylene strips of 8 wells each held in a rigid frame. Ideal for antibody assays....
...
... Pierce scientists developed the Easy-Titer Human IgM ... a simple, sensitive, and easy-to-perform assay for ... an ELISA. This kit incorporates a simple ... of IgM concentration from 15-500 ng/ml in ...
Biology Products: